Why the study?
Do antiplatelet agents reduce cardiovascular mortality in hemodialysis patients?
Population
Patients with chronic renal failure requiring chronic hemodialysis
Design
Review
Authors
Loading...
Higher MI risk in CRF patients on antiplatelets/anticoagulants warrants individualized assessment; leaves open optimal regimens in hemodialysis.
Do antiplatelet agents reduce cardiovascular mortality in hemodialysis patients?
Aspirin may be reasonable for secondary prevention in hemodialysis patients, but dual antiplatelet therapy increases bleeding risk without clear mortality benefit.
Migliori et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: